Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2004 Mar;50:388–394.

Treating bipolar disorder. Evidence-based guidelines for family medicine.

Roger S McIntyre 1, Deborah A Mancini 1, Peter Lin 1, John Jordan 1
PMCID: PMC2214573  PMID: 15318676

Abstract

OBJECTIVE: To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office. QUALITY OF EVIDENCE: Articles from 1990 to 2003 were selected from MEDLINE using the key words "bipolar disorder," "antiepileptics," "antipsychotics," "antidepressants," and "mood stabilizers." Good-quality evidence for many of these treatments comes from randomized trials. Lithium, divalproex, carbamazepine, lamotrigine, oxcarbazepine, and some novel antipsychotics all have level I evidence for treating various aspects of the disorder. MAIN MESSAGE: Treatment of bipolar disorder involves three therapeutic domains: acute mania, acute depression, and maintenance. Lithium has been a mainstay of treatment for some time, but antiepileptic drugs like divalproex, carbamazepine, and lamotrigine, along with novel antipsychotic drugs like olanzapine, risperidone, and quetiapine, alone or in combination, are increasingly being used successfully to treat acute mania and to maintain mood stability. CONCLUSION: Bipolar disorder is more common in family practice than previously believed. Drug treatments for this complex disorder have evolved rapidly over the past decade, radically changing its management. Treatment now tends to be very successful.

Full Text

The Full Text of this article is available as a PDF (244.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiskal H. S., Bourgeois M. L., Angst J., Post R., Möller H., Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000 Sep;59 (Suppl 1):S5–S30. doi: 10.1016/s0165-0327(00)00203-2. [DOI] [PubMed] [Google Scholar]
  2. Baldessarini R. J., Tondo L., Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci. 2001 Apr;932:24–43. doi: 10.1111/j.1749-6632.2001.tb05796.x. [DOI] [PubMed] [Google Scholar]
  3. Bowden C. L. Novel treatments for bipolar disorder. Expert Opin Investig Drugs. 2001 Apr;10(4):661–671. doi: 10.1517/13543784.10.4.661. [DOI] [PubMed] [Google Scholar]
  4. Calabrese J. R., Woyshville M. J. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psychiatry. 1995 Jun;7(2):103–112. doi: 10.3109/10401239509149036. [DOI] [PubMed] [Google Scholar]
  5. Conley R. R., Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001 May;158(5):765–774. doi: 10.1176/appi.ajp.158.5.765. [DOI] [PubMed] [Google Scholar]
  6. De León O. A. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry. 2001 Sep-Oct;9(5):209–222. doi: 10.1093/hrp/9.5.209. [DOI] [PubMed] [Google Scholar]
  7. Ghaemi S. N., Cherry E. L., Katzow J. A., Goodwin F. K. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2000 Sep;2(3 Pt 1):196–199. doi: 10.1034/j.1399-5618.2000.020307.x. [DOI] [PubMed] [Google Scholar]
  8. Ghaemi S. N. On defining 'mood stabilizer'. Bipolar Disord. 2001 Jun;3(3):154–158. doi: 10.1034/j.1399-5618.2001.030304.x. [DOI] [PubMed] [Google Scholar]
  9. Ghaemi S. N., Sachs G. S., Chiou A. M., Pandurangi A. K., Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord. 1999 Jan-Mar;52(1-3):135–144. doi: 10.1016/s0165-0327(98)00076-7. [DOI] [PubMed] [Google Scholar]
  10. Gray S. M., Otto M. W. Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. J Clin Psychiatry. 2001;62 (Suppl 25):56–64. [PubMed] [Google Scholar]
  11. Hirschfeld R. M., Williams J. B., Spitzer R. L., Calabrese J. R., Flynn L., Keck P. E., Jr, Lewis L., McElroy S. L., Post R. M., Rapport D. J. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov;157(11):1873–1875. doi: 10.1176/appi.ajp.157.11.1873. [DOI] [PubMed] [Google Scholar]
  12. Hirschfeld Robert M. A., Calabrese Joseph R., Weissman Myrna M., Reed Michael, Davies Marilyn A., Frye Mark A., Keck Paul E., Jr, Lewis Lydia, McElroy Susan L., McNulty James P. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003 Jan;64(1):53–59. doi: 10.4088/jcp.v64n0111. [DOI] [PubMed] [Google Scholar]
  13. Hirschfeld Robert M. A., Holzer Charles, Calabrese Joseph R., Weissman Myrna, Reed Michael, Davies Marilyn, Frye Mark A., Keck Paul, McElroy Susan, Lewis Lydia. Validity of the mood disorder questionnaire: a general population study. Am J Psychiatry. 2003 Jan;160(1):178–180. doi: 10.1176/appi.ajp.160.1.178. [DOI] [PubMed] [Google Scholar]
  14. Howland R. H. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol. 1996 Dec;16(6):425–427. doi: 10.1097/00004714-199612000-00003. [DOI] [PubMed] [Google Scholar]
  15. Hummel Barbara, Walden Joerg, Stampfer Robert, Dittmann Sandra, Amann Benedikt, Sterr Andrea, Schaefer Martin, Frye Mark A., Grunze Heinz. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord. 2002 Dec;4(6):412–417. doi: 10.1034/j.1399-5618.2002.02228.x. [DOI] [PubMed] [Google Scholar]
  16. Keck P. E., Jr, Wilson D. R., Strakowski S. M., McElroy S. L., Kizer D. L., Balistreri T. M., Holtman H. M., DePriest M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry. 1995 Oct;56(10):466–470. [PubMed] [Google Scholar]
  17. Kennedy S. H., Lam R. W., Cohen N. L., Ravindran A. V., CANMAT Depression Work Group Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001 Jun;46 (Suppl 1):38S–58S. [PubMed] [Google Scholar]
  18. Kessing L. V., Andersen P. K., Mortensen P. B. Predictors of recurrence in affective disorder. A case register study. J Affect Disord. 1998 May;49(2):101–108. doi: 10.1016/s0165-0327(97)00163-8. [DOI] [PubMed] [Google Scholar]
  19. Lish J. D., Dime-Meenan S., Whybrow P. C., Price R. A., Hirschfeld R. M. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994 Aug;31(4):281–294. doi: 10.1016/0165-0327(94)90104-x. [DOI] [PubMed] [Google Scholar]
  20. Lopez A. D., Murray C. C. The global burden of disease, 1990-2020. Nat Med. 1998 Nov;4(11):1241–1243. doi: 10.1038/3218. [DOI] [PubMed] [Google Scholar]
  21. Maj M., Pirozzi R., Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry. 1995 Dec;152(12):1810–1811. doi: 10.1176/ajp.152.12.1810. [DOI] [PubMed] [Google Scholar]
  22. Malkoff-Schwartz S., Frank E., Anderson B. P., Hlastala S. A., Luther J. F., Sherrill J. T., Houck P. R., Kupfer D. J. Social rhythm disruption and stressful life events in the onset of bipolar and unipolar episodes. Psychol Med. 2000 Sep;30(5):1005–1016. doi: 10.1017/s0033291799002706. [DOI] [PubMed] [Google Scholar]
  23. Manning J. S., Haykal R. F., Connor P. D., Akiskal H. S. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry. 1997 Mar-Apr;38(2):102–108. doi: 10.1016/s0010-440x(97)90089-4. [DOI] [PubMed] [Google Scholar]
  24. McIntyre R. S., McCann S. M., Kennedy S. H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001 Apr;46(3):273–281. doi: 10.1177/070674370104600308. [DOI] [PubMed] [Google Scholar]
  25. McIntyre Roger S., Mancini Deborah A., McCann Sonia, Srinivasan Janaki, Sagman Doron, Kennedy Sidney H. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002 Jun;4(3):207–213. doi: 10.1034/j.1399-5618.2002.01189.x. [DOI] [PubMed] [Google Scholar]
  26. Ostroff R. B., Nelson J. C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999 Apr;60(4):256–259. doi: 10.4088/jcp.v60n0410. [DOI] [PubMed] [Google Scholar]
  27. Piver Andre, Yatham Lakshmi N., Lam Raymond W. Bipolar spectrum disorders. New perspectives. Can Fam Physician. 2002 May;48:896–904. [PMC free article] [PubMed] [Google Scholar]
  28. Ramasubbu R. Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatr Scand. 2001 Sep;104(3):236–239. doi: 10.1034/j.1600-0447.2001.00383.x. [DOI] [PubMed] [Google Scholar]
  29. Rothenberg A. Bipolar illness, creativity, and treatment. Psychiatr Q. 2001 Summer;72(2):131–147. doi: 10.1023/a:1010367525951. [DOI] [PubMed] [Google Scholar]
  30. Sachs Gary S., Grossman Fred, Ghaemi S. Nassir, Okamoto Akiko, Bowden Charles L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002 Jul;159(7):1146–1154. doi: 10.1176/appi.ajp.159.7.1146. [DOI] [PubMed] [Google Scholar]
  31. Shelton R. C., Tollefson G. D., Tohen M., Stahl S., Gannon K. S., Jacobs T. G., Buras W. R., Bymaster F. P., Zhang W., Spencer K. A. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan;158(1):131–134. doi: 10.1176/appi.ajp.158.1.131. [DOI] [PubMed] [Google Scholar]
  32. Siris S. G. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry. 2000 Sep;157(9):1379–1389. doi: 10.1176/appi.ajp.157.9.1379. [DOI] [PubMed] [Google Scholar]
  33. Tohen M., Jacobs T. G., Feldman P. D. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000 Sep;2(3 Pt 2):261–268. doi: 10.1034/j.1399-5618.2000.20307.x. [DOI] [PubMed] [Google Scholar]
  34. Tollefson G. D., Andersen S. W. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry. 1999;60 (Suppl 5):23–30. [PubMed] [Google Scholar]
  35. Tondo L., Baldessarini R. J., Hennen J., Minnai G. P., Salis P., Scamonatti L., Masia M., Ghiani C., Mannu P. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry. 1999;60 (Suppl 2):63-9; discussion 75-6, 113-6. [PubMed] [Google Scholar]
  36. Tondo L., Baldessarini R. J. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry. 2000;61 (Suppl 9):97–104. [PubMed] [Google Scholar]
  37. Tondo L., Hennen J., Baldessarini R. J. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 2001 Sep;104(3):163–172. doi: 10.1034/j.1600-0447.2001.00464.x. [DOI] [PubMed] [Google Scholar]
  38. Tran P. V., Hamilton S. H., Kuntz A. J., Potvin J. H., Andersen S. W., Beasley C., Jr, Tollefson G. D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 Oct;17(5):407–418. doi: 10.1097/00004714-199710000-00010. [DOI] [PubMed] [Google Scholar]
  39. Yassa R., Ghadirian A. M., Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry. 1983 Nov;44(11):410–412. [PubMed] [Google Scholar]
  40. Zerjav-Lacombe S., Tabarsi E. Lamotrigine: a review of clinical studies in bipolar disorders. Can J Psychiatry. 2001 May;46(4):328–333. doi: 10.1177/070674370104600403. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES